NDAORALTABLETPriority Review
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
Priority Review
INQOVI (cedazuridine and decitabine) by Taiho Oncology is nucleic acid synthesis inhibitors [moa]. Approved for nucleoside metabolic inhibitor [epc]. First approved in 2020.
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INQOVI is an oral tablet combination of cedazuridine and decitabine approved by the FDA on July 7, 2020, for treating myelodysplastic syndromes (MDS). It functions as a nucleoside metabolic inhibitor that inhibits nucleic acid synthesis. Cedazuridine enhances decitabine bioavailability by inhibiting cytidine deaminase, enabling oral dosing of decitabine which was previously only available intravenously. The product represents a meaningful advance in MDS treatment by offering patients an oral alternative to IV infusion.
$0.1BPart D
14.8 years to LOEMechanism of Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Class:
Nucleoside Metabolic Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Inqovi Maintenance Therapy in Myeloid Neoplasms
Started Sep 2021
22 enrolled
Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaStem Cell Leukemia
Career Relevance
INQOVI supports specialty oncology roles including brand managers, oncology-focused medical science liaisons (MSLs), and hematology field teams targeting hematologists and oncologists. Success in this product requires deep knowledge of MDS pathophysiology, comparative efficacy with IV alternatives, and patient access navigation for this high-cost specialty therapy. Currently, zero open positions are linked to INQOVI in available job tracking data, though the product's peak lifecycle stage suggests stable team staffing rather than expansion hiring.
Worked on INQOVI at Taiho Oncology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.